Effects of atomoxetine on growth in children with attention-deficit/ hyperactivity disorder following up to five years of treatment

Journal of Child and Adolescent Psychopharmacology

Volumn 17, Issue 5, 2007, Pages 689-699

  Spencer, Thomas J ^a   Kratochvil, Christopher J ^b   Sangal, R Bart ^c   Saylor, Keith E ^d   Bailey, Charles E ^e   Dunn, David W ^f   Geller, Daniel A ^a   Casat, Charles D ^g   Lipetz, Robert S ^h   Jain, Rakesh ⁱ   Newcorn, Jeffrey H ^j   Ruff, Dustin D ^k   Feldman, Peter D ^k   Furr, Amanda J ^f   Allen, Albert J ^k  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c Attention Disorders Institute   (United States)

^d NeuroScience Inc   (United States)

^e Psychiatric Institute of Florida   (United States)

^f INDIANA UNIVERSITY   (United States)

^g LEVINE CANCER INSTITUTE   (United States)

^h Encompass Clinical Research   (United States)

ⁱ R/D Clinical Research Inc   (United States)

^j MOUNT SINAI MEDICAL CENTER   (United States)

^k ELI LILLY AND COMPANY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BODY HEIGHT; CHILD; CHILD GROWTH; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; SIDE EFFECT; TREATMENT DURATION; WEIGHT REDUCTION;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; CHILD; FEMALE; GROWTH; HUMANS; LONGITUDINAL STUDIES; MALE; PROPYLAMINES; PSYCHIATRIC STATUS RATING SCALES;

EID: 35848960802     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.0100     Document Type: Article

References (37)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington (DC), American Psychiatric Association, 1994.
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). Washington (DC), American Psychiatric Association, 2000.
3. Andres Carrasco MA, Catala MA, Gomez-Beneyto M: Study of the prevalence of the attention deficit hyperactivity disorder in ten-year-old children living in the Valencia metropolitan area. Actas Luso Esp Neurol Psiquiatr Cienc Afines 23:184-188, 1995.
4. Bazar KA, Yun AJ, Lee PY, Daniel SM, Doux JD: Obesity and ADHD may represent different manifestations of a common environmental oversampling syndrome: A model for revealing mechanistic overlap among cognitive, metabolic, and inflammatory disorders. Med Hypotheses 66:263-269, 2006.
5. Charach A, Figueroa M, Chen S, Ickowicz A, Schachar R: Stimulant treatment over 5 years: Effects on growth. J Am Acad Child Adolesc Psychiatry 45:415-421, 2006.
6. Curtin C, Bandini LG, Perrin EC, Tybor DJ, Must A: Prevalence of overweight in children and adolescents with attention deficit hyperactivity disorder and autism spectrum disorders: A chart review. BMC Pediatrics 5:48, 2005.
7. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York, The Guilford Press, 1998.
8. Faraone SV, Biederman J, Monuteaux M, Spencer T: Longterm effects of extended-release mixed amphetamine salts treatment for attention-deficit/ hyperactivity disorder on growth. J Child Adolesc Psychopharmacol 15:191-202, 2005a.
9. Faraone SV, Biederman J, Spencer TJ, Michelson D, Adler LA, Reimherr FW, Glatt SJ: Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: A drug-placebo response curve analysis. Behav Brain Funct 1:16, 2005b.
10. Faries DE, Yalcin I, Harder D, Heiligenstein JH: Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord 5:39-47, 2001.
11. Freed SC, Mizel M: The use of amphetamine combinations for appetite suppression. Ann Int Med 36:1492-1497, 1952.
12. Holtkamp K, Konrad K, Müller B, Heussen N, Herpertz S, Herpertz-Dahlmann B, Hebebrand J: Overweight and obesity in children with attention-deficit/hyperactivity disorder. Int J Obes 28:685-689, 2004.
13. Kaufman J, Birmaher B, Brent D, Rao U, Ryan N: Kiddie-SADS-Present and Lifetime Version (K-SADS-PL). Pittsburgh, University of Pittsburgh Press, 1996.
14. Kramer JR, Loney J, Ponto LB, Roberts MA, Grossman S: Predictors of adult height and weight in boys treated with methylphenidate for childhood behavior problems. J Am Acad Child Adolesc Psychiatry 39:517-524, 2000.
15. Kratochvil CJ, Wernicke JF, Michelson D, Vaughan B, Bohac D, Harrington M, Baker N, May D, Burke WJ: Long-term safety of atomoxetine in the treatment of ADHD. Presented at The 48th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, October 23-28, 2001, Honolulu, HI, Abstract number P119.
16. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Baker KD, Feldman PD, Gelowitz DL: Effects of long-term atomoxetine treatment for young children with attentiondeficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:919-927, 2006.
17. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, Mei Z, Curtin LR, Roche AF, Johnson CL: CDC growth charts: United States. Advance data from vital and health statistics. Report Nr. 314. Hyattsville (Maryland), National Center for Health Statistics, 2000.
18. Lisska MC, Rivkees SA: Daily methylphenidate use slows the growth of children: A community based study. J Pediatr Endocrinol Metab 16:711-718, 2003.
19. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T, Atomoxetine ADHD Study Group: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 108:e83, 2001.
20. Michelson D, Spencer T, Bangs M, Zhang S, Ruff D, Gao H, Feldman P: Developmental outcomes of long-term atomoxetine treatment in ADHD. Presented at The 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, October 19-24, 2004; Washington, DC. Abstract number A2.
21. MTA Cooperative Group: National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: Changes in effectiveness and growth after the end of treatment. Pediatrics 113:762-769, 2004.
22. Pliszka SR, Matthews TL, Braslow KJ, Watson MA: Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:520-526, 2006.
23. Poindexter A: Appetite suppressant drugs: A controlled clinical comparison of benzphetamine, phenmetrazine, d-amphetamine and placebo. Curr Ther Res Clin Exp 2:354-363, 1960.
24. Poulton A, Cowell CT: Slowing of growth in height and weight on stimulants: A characteristic pattern. J Paediatr Child Health 39:180-185, 2003.
25. Safer D, Allen R, Barr E: Depression of growth in hyperactive children on stimulant drugs. N Engl J Med 287:217-220, 1972.
26. Satterfield JH, Cantwell DP, Schell A, Blaschke T: Growth of hyperactive children treated with methylphenidate. Arch Gen Psychiatry 36:212-217, 1979.
27. Schertz M, Adesman AR, Alfieri NE, Bienkowski RS: Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication. Pediatrics 98:763-769, 1996.
28. Spencer TJ, Biederman J, Harding M, O'Donnell D, Faraone SV, Wilens TE: Growth deficits in ADHD children revisited: Evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry 35:1460-1469, 1996.
29. Spencer TJ, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63:1140-1147, 2002.
30. Spencer TJ, Newcorn JH, Kratochvil CJ, Ruff D, Michelson D, Biederman J: Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. Pediatrics 116:e74-e80, 2005.
31. Spencer TJ, Faraone SV, Biederman J, Lerner M, Cooper KM, Zimmerman B, Concerta Study Group: Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD? J Am Acad Child Adolesc Psychiatry 45:527-537, 2006.
32. Sund AM, Zeiner P: Does extended medication with amphetamine or methylphenidate reduce growth in hyperactive children? Nord J Psychiatry 56:53-57, 2002.
33. Wang YC, Chong MY, Chou WJ, Yang JL: Prevalence of attention deficit hyperactivity disorder in primary school children in Taiwan. J Formos Med Assoc 92:133-138, 1993.
34. Wellman PJ: Norepinephrine and the control of food intake. Nutrition 16:837-842, 2000.
35. Wilens TE, Kratochvil C, Newcorn JH, Gao H: Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child Adolesc Psychiatry 45:149-157, 2006.
36. World Medical Association: Declaration of Helsinki: Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects. As adopted by the 18th World Medical Association General Assembly, Helsinki, Finland, June 1964 and amended by the 52nd General Assembly, Edinburgh, Scotland, October 2000.
37. Zachor DA, Roberts AW, Hodgens JB, Isaacs JS, Merrick J: Effects of long-term psychostimulant medication on growth of children with ADHD. Res Dev Disabil 27:162-174, 2006.